Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate ...

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Self-service data analytics company Gigasheet announced a new digital platform designed to enhance healthcare price ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, explores what kind of role ...

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...